根治性放疗在高龄体弱上尿路尿路上皮癌患者中的肿瘤学结局
回顾性分析63例接受根治性放疗的体弱UTUC患者,按BED10≥74.3 Gy分为高剂量组。高剂量组疾病控制率98% vs 62%,3年OS 46% vs 11%,多因素分析示放疗剂量是FFP和OS的独立预后因素。
要点
- 高剂量放疗显著改善体弱UTUC患者的疾病控制率和总生存。
- 放疗前肉眼血尿和年龄校正Charlson合并症指数>5与更差OS相关。
- 高剂量放疗可作为体弱UTUC患者的安全替代方案。
核心结论
- 根治性放疗在UTUC中呈现明确的剂量-反应关系,高剂量放疗与显著改善的生存相关,是体弱患者的安全替代方案。
研究设计与样本
- 多中心回顾性研究,纳入2014-2021年四家学术医院接受根治性放疗的63例UTUC患者,年龄校正Charlson合并症指数≥3。
- 按BED10 cutoff 74.3 Gy分为高剂量组和低剂量组,采用IPTW调整基线失衡后行Cox回归和Kaplan-Meier分析。
主要发现
- 中位随访76个月,骨盆输尿管最常受累(57%),其次为肾盂(33%)和腹段输尿管(21%)。
- IPTW调整后,高剂量组疾病控制率显著更高(98% vs 62%,P < 0.001)。
- 高剂量组显著改善3年LRC(51% vs 29%,P = 0.041)、FFDM(75% vs 39%,P = 0.001)、FFP(43% vs 25%,P = 0.013)和OS(46% vs 11%,P < 0.001)。
- 多因素分析显示更高放疗剂量是改善FFP(aHR 0.96,P = 0.018)和OS(aHR 0.93,P < 0.001)的独立预后因素。
- 放疗前肉眼血尿(aHR 2.63,P = 0.002)和年龄校正Charlson合并症指数>5(aHR 2.85,P = 0.007)与更差OS相关。
关键数值与推荐
- 高剂量组BED10中位84.0 Gy(IQR 78.4-86.4),低剂量组中位64.8 Gy(IQR 60.0-72.0)。
- BED10 cutoff为74.3 Gy(源自63 Gy/35次,假设α/β比=10)。
临床怎么用
- 对医学上体弱的UTUC患者,根治性放疗应尽量给予高剂量(BED10≥74.3 Gy)以改善肿瘤控制与生存。
- 放疗前肉眼血尿和年龄校正Charlson合并症指数>5提示预后更差,可用于风险分层。
局限性
- 回顾性研究,样本量较小(63例),存在选择偏倚可能。
- 高剂量与低剂量组的剂量定义基于BED10 cutoff,α/β比假设为10。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate oncologic outcomes of high-dose radical radiotherapy (RT) in medically frail patients with upper tract urothelial carcinoma (UTUC). MATERIALS AND METHODS: We retrospectively reviewed 63 patients with UTUC who received definitive RT at four major academic hospitals (2014-2021) with significant comorbidities (age-adjusted Charlson Comorbidity Index ≥3). Patients were stratified into high- and low-dose groups using a biologically effective dose (BED10) cutoff of 74.3 Gy (from 63 Gy/35 fractions, assuming α/β ratio = 10). The median BED10 was 64.8 Gy (interquartile range 60.0-72.0) in the low-dose group and 84.0 Gy (interquartile range 78.4-86.4) in the high-dose group. Baseline imbalances were addressed using inverse probability of treatment-weighted (IPTW) in Cox proportional hazard models and Kaplan-Meier analyses. RESULTS: The median follow-up was 76 months. The pelvic ureter was the most frequently involved site (57%), followed by the renal pelvis (33%) and the abdominal ureter (21%). In the IPTW-adjusted cohort, the disease control rate was significantly higher with high-dose RT (98% vs 62%, P < 0.001). High-dose RT significantly improved IPTW-adjusted locoregional control (3-year LRC: 51% vs 29%, P = 0.041), freedom from distant metastasis (3-year FFDM: 75% vs 39%, P = 0.001), freedom from progression (3-year FFP: 43% vs 25%, P = 0.013), and overall survival (3-year OS: 46% vs 11%, P < 0.001). Multivariate analysis identified higher RT dose as an independent prognosticator of improved FFP (adjusted hazard ratio [aHR] 0.96, P = 0.018) and OS (aHR 0.93, P < 0.001). Furthermore, pre-RT gross haematuria (aHR 2.63, P = 0.002) and age-adjusted Charlson Comorbidity Index >5 (aHR 2.85, P = 0.007) were associated with worse OS. CONCLUSION: A clear dose-response relationship was observed in UTUC treated with definitive RT. High-dose RT was associated with significantly improved survival and represents a safe alternative for medically frail patients.
引用
- Chen WP, Yap WK, Luo HL, et al. Oncologic outcomes of radical radiotherapy in frail patients with upper tract urothelial carcinoma. BJU Int. 2026. PMID: 42533861. doi:10.1111/bju.70392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。